Proyectos
Estratégicos

PRotección integral de afecciOnes inMunocirculatorias En la Tercera Edad (Comprehensive Protection of Immunocirculatory Conditions in the Elderly) 

In Europe, it is estimated that more than 10 million people suffer from pressure ulcers (PU); a condition with an incidence in the adult population of between 5% and 12%, reaching 20% in geriatric patients with acute and/or chronic diseases. The environment of these wounds and their progression — particularly exacerbated in bedridden individuals due to body pressure and friction with clothing and bedding — means that new technologies and antimicrobial textiles play a significant role in improving therapeutic approaches and ensuring a better quality of life.

In this regard, the general objective of the PROMETEA project is to achieve combined treatments that enable the regeneration of epithelia while controlling infection and inflammation processes. This will be accomplished through the prevention of infections and the stimulation of the defences of affected individuals. Thanks to the collaboration of ADItech in this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project’s objective more effectively. This work has been made possible thanks to the collaboration of  Olaya Fernández Guerrero and Remedios Álvarez Terán of the University of La Rioja. 

Bioingeniería avanzada para el desarrollo del tejido cardiaco y su aplicación al estudio y detección de cardiotoxicidad

This project tackles the challenge of advancing 3D printing technology and biomaterials to enable the development of human cardiac tissue in the laboratory, ranging from mini-hearts to complete organs. Additionally, it aims to establish them as an effective and innovative platform for the early detection of cardiotoxicity.

The objective is to position Navarre as an innovation node in the development of biofabrication technology and the production of bio-artificial human heart tissues. Additionally, it aims to utilize these tissues for industrial and (pre-) clinical testing of cardiotoxicity.

The consortium behind this project will work on the development of technological and biomedical tools for the design, development, manufacture and implementation of cardiotoxicity testing platforms, with different capacities. It will also proactively evaluate their valorisation. This will be based on state-of-the-art technology: from human iPSC stem cells, multifunctional 3D printing and biomaterials, to the in vivo generation of humanised hearts by blastocyst complementation.

Thanks to the collaboration of ADItech in this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project’s objective more effectively. This work has been made possible thanks to the collaboration of Lourdes Chacon-Alberty of the Texas Heart Institute.